Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

BACKGROUND: Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase strand-transfer inhibitor. We report final results of BENCHMRK-1 and BENCHMRK-2 combined at 3 years (the end of the double-blind phase) and 5 years...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Infect Dis
Main Authors: Eron, Joseph J, Cooper, David A, Steigbigel, Roy T, Clotet, Bonaventura, Gatell, Jose M, Kumar, Princy N, Rockstroh, Jurgen K, Schechter, Mauro, Markowitz, Martin, Yeni, Patrick, Loutfy, Mona R, Lazzarin, Adriano, Lennox, Jeffrey L, Strohmaier, Kim M, Wan, Hong, Barnard, Richard J O, Nguyen, Bach-Yen T, Teppler, Hedy
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6083850/
https://ncbi.nlm.nih.gov/pubmed/23664333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(13)70093-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items